N/A N=30 Aspiration of Limited Number of Follicles to Prevent Severe Ovarian Hyperstimulation Syndrome
Infertility
Primary: Number of Participants of Severe Ovarian Hyperstimulation Syndrome — 2; 11 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=20 The Role of Cetrotide Acetate in Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in Oocyte Donors
Ovarian Hyperstimulation Syndrome
Primary: Volume of Ascites in the Abdomen is Indicative of the Severity of OHSS — 10 cc (volume of ascites)
Phase 4 N=71 Co-administration of Low Dose hCG at the Time of GnRH Agonist Trigger or 35 Hours Later for the Prevention of OHSS
Ovarian Hyperstimulation Syndrome
Primary: Ongoing Pregnancy — 15; 19 participants
Phase 4 N=112 Follicular Steroid Genesis in Controlled Ovarian Stimulation
Infertility · Controlled Ovarian Hyperstimulation
Primary: SERUM PROGSTERONE CONCENTRATION — 0.74; 0.45 ng/mL — p=<0.05
Phase 4 N=226 Obesity, Oral Contraception, and Ovarian Suppression
Ovarian Suppression
Primary: Risk of Oral Contraceptive (OC) Failure Due to Less Contraceptive-mediated Ovarian Suppression. — 54; 28; 11; 12 Participants
Phase 2 N=60 Assessment and Prevention of Pain During Ovarian Stimulation in Patients With Endometriosis
Endometriosis · Ovarian Hyperstimulation
Primary: Average Delta in Endometriosis Pain Score Pre and Post Stimulation With and Without Use Of Letrozole — -2.5; -2.7 Change in score on a scale
Phase 4 N=442 Predictive Factors for Ovarian Stimulation Using a Fixed Daily Dose of 200 IU Recombinant FSH (Study 142003)(P05696)
Infertility
Primary: Total Number of Oocytes — 12.4; 12.1 Number of oocytes
N/A N=96 Differential Regulation of VEGF, Cadherin, Angiopietin 2 by Trigger Oocyte Maturation With GnRHa vs hCG in Donors
Vascular Endothelial Growth Factor Overexpression
Primary: VEGF Protein and mRNA Levels — 1395; 1069; 1666 pg/ml — p=<0.001
Phase 3 N=105 Administration of Follicle-stimulating Hormone (FSH) and Low Dose Human Chorionic Gonadotropin (hCG) for Oocyte Maturity While Decreasing hCG Exposure in In Vitro Fertilization (IVF) Cycles
Infertility
Primary: Total Fertilization Proportion (i.e. Total Competent Proportion) — 0.59; 0.65 ratio
Phase 3 N=27 Immunogenicity of Repeated Follicle Stimulating Hormone (FSH) Stimulation Cycles
Oocyte Donation
Primary: Number of Patients Producing Anti-FSH Antibodies. — 0 participants
Phase 3 N=24 Theca Cell Function in Adolescents With Polycystic Ovary Syndrome (PCOS)
PCOS
Primary: 17OHP Levels After hCG — 3.2; 1.3 ng/ml
Phase 4 N=110 Menopur® Versus Follistim® in Polycystic Ovarian Syndrome (PCOS)
Polycystic Ovarian Syndrome · Infertility
Primary: Participants With Cycle Cancellation Due to Risk of Ovarian Hyperstimulation Syndrome (OHSS) Between Weeks 1 - 3 — 1; 0; 1; 0 Participants — p=1.000
Phase 3 N=82 Induction of Ovulation With Raloxifene or Clomiphene Citrate in Polycystic Ovarian Syndrome
Polycystic Ovary Syndrome
Primary: Percentage of Participants With Ovulation Detected by Ultrasound — 52.5; 40.4 percentage of participants — p=0.3
Early Phase 1 N=100 Ovulation Induction in Women With Clomiphene Citrate Resistant PCOS
Polycystic Ovary Syndrome · Infertility
Primary: Ovulation Rate — 93; 108 percentage of all cycles
N/A N=79 Evaluation of Ovarian Morphology and Function in Overweight Women During Weight Loss
Weight Loss · Anovulation · Amenorrhea
Primary: Change From Baseline Ovulatory/Menstrual Function — 12; 18 Participants
Phase 4 N=30 Continuous Double Ovarian Stimulation.
Fertility Issues
Primary: Total Number of Retrieved Oocytes — 13.33; 11.87 oocytes
Phase 3 N=39 LutrePulse Hypogonadotropic Hypogonadism
Primary Amenorrhea With Hypogonadotropic Hypogonadism
Primary: Ovulation Rate — 1; 4; 5; 9 Participants — p=0.0120
Phase 3 N=900 Assessment of Multiple Intrauterine Gestations From Ovarian Stimulation
Pregnancy · Unexplained Infertility
Primary: Multiple Gestation Rate Following Recruitment of Multiple Follicular Development With an AI, as Compared to CC and FSH. — 9; 8; 34 number of multiples
Phase 3 N=750 Pregnancy in Polycystic Ovary Syndrome II
Pregnancy · Polycystic Ovary Syndrome
Primary: Live Birth — 72; 103 Participants — p=0.007
N/A N=49 Feasibility Study for Development of an Early Test for Ovarian Failure
Healthy · Premature Ovarian Failure
Primary: Follicle Stimulating Hormone Stimulated Serum Inhibin B Levels. — 50.7; 48.8; 96.6; 47.7 participants
Phase 3 N=52 A Prospective Study to Evaluate the Addition of Subcutaneous Recombinant Human-Luteinizing Hormone With Recombinant Human-Follicle Stimulating Hormone on Follicular Development in Women Undergoing Ovarian Stimulation for Assisted Reproductive Technologies
Infertility · Ovarian Stimulation
Primary: Mean Number of Metaphase II Oocytes Per Participant Who Underwent Ovum Pick up for Intra-cytoplasmic Sperm Injection (ICSI) — 9.5 Metaphase II Oocytes
Phase 2 N=65 A Study of AZD4901 in Females With Polycystic Ovary Syndrome
Polycystic Ovary Syndrome (PCOS), Female Endocrine Disorder
Primary: Lutenising Hormone (LH) AUC(0-8) Ratio to Baseline at Day 7 — 1.118; 0.9729; 0.8804; 0.5364 Ratio
Phase 3 N=25 Theca Cell Function in Women With Polycystic Ovary Syndrome (PCOS)
Polycystic Ovary Syndrome
Primary: Serum 17OHP Responses to hCG — 2.0; 1.2; 1.1; 1.0 ng/ml — p=<0.05
Phase 3 N=397 To Investigate Efficacy and Safety of a Single Injection of Org 36286 for Ovarian Stimulation Using Daily Recombinant FSH as Reference (Ensure)(P05690/MK-8962-001)
Infertility
Primary: Number of Cumulus-oocyte-complexes Retrieved, Per Attempt — 13.3; 10.6 Number of cumulus-oocyte-complexes — p=<0.001
Phase 3 N=176 A Randomised Trial Using Highly Purified Human Chorionic Gonadotropin (HP-hCG) and Recombinant Human Chorionic Gonadotropin (rhCG) in Women Undergoing Controlled Ovarian Stimulation
Infertility
Primary: Number of Oocytes Retrieved — 7.1; 7.3; 6.6 Number of oocytes
Phase 3 N=1,011 Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Pan-Asian Women
Controlled Ovarian Simulation
Primary: Ongoing Pregnancy Rate — 31.3; 25.7 percentage of participants
N/A N=30 Estrogen Sensitivity and Ovulatory Dysfunction in Obesity
Obesity · Infertility
Primary: Luteinizing Hormone Pulse Amplitude — 2.73; 1.12 IU/L
Phase 2 N=149 Treatment of Hyperandrogenism Versus Insulin Resistance in Infertile Polycystic Ovary Syndrome (PCOS) Women
Polycystic Ovary Syndrome
Primary: Live Birth Rate — 13; 5; 12 participants — p=0.06
Phase 3 N=19 Primary Ovarian Insufficiency: Phenotype and Optimal Treatment
Primary Ovarian Insufficiency
Primary: Change in Dual Energy X-ray Absorptiometry (DXA) Measure of Bone Mineral Density (BMD) of the Lumbar Spine — 0.228; 0.673 Z-score
N/A N=290 To Study Polycystic Ovary Syndrome in Taiwanese Women
Polycystic Ovary Syndrome · Metabolic Syndrome · Cardiovascular Disease
Primary: Total Testosterone — 1.5; 2.9 nmol/L — p=<0.05